Literature DB >> 27900518

The reconstruction algorithm used for [68Ga]PSMA-HBED-CC PET/CT reconstruction significantly influences the number of detected lymph node metastases and coeliac ganglia.

Thomas Krohn1,2, Anita Birmes3, Oliver H Winz3, Natascha I Drude3, Felix M Mottaghy3,4, Florian F Behrendt3,5, Frederik A Verburg3,6.   

Abstract

PURPOSE: To investigate whether the numbers of lymph node metastases and coeliac ganglia delineated on [68Ga]PSMA-HBED-CC PET/CT scans differ among datasets generated using different reconstruction algorithms.
METHODS: Data were constructed using the BLOB-OS-TF, BLOB-OS and 3D-RAMLA algorithms. All reconstructions were assessed by two nuclear medicine physicians for the number of pelvic/paraaortal lymph node metastases as well the number of coeliac ganglia. Standardized uptake values (SUV) were also calculated in different regions.
RESULTS: At least one [68Ga]PSMA-HBED-CC PET/CT-positive pelvic or paraaortal lymph node metastasis was found in 49 and 35 patients using the BLOB-OS-TF algorithm, in 42 and 33 patients using the BLOB-OS algorithm, and in 41 and 31 patients using the 3D-RAMLA algorithm, respectively, and a positive ganglion was found in 92, 59 and 24 of 100 patients using the three algorithms, respectively. Quantitatively, the SUVmean and SUVmax were significantly higher with the BLOB-OS algorithm than with either the BLOB-OS-TF or the 3D-RAMLA algorithm in all measured regions (p < 0.001 for all comparisons). The differences between the SUVs with the BLOB-OS-TF- and 3D-RAMLA algorithms were not significant in the aorta (SUVmean, p = 0.93; SUVmax, p = 0.97) but were significant in all other regions (p < 0.001 in all cases). The SUVmean ganglion/gluteus ratio was significantly higher with the BLOB-OS-TF algorithm than with either the BLOB-OS or the 3D-RAMLA algorithm and was significantly higher with the BLOB-OS than with the 3D-RAMLA algorithm (p < 0.001 in all cases).
CONCLUSION: The results of [68Ga]PSMA-HBED-CC PET/CT are affected by the reconstruction algorithm used. The highest number of lesions and physiological structures will be visualized using a modern algorithm employing time-of-flight information.

Entities:  

Keywords:  PSMA PET/CT; PSMA-HBED-CC; Prostate cancer; Reconstruction algorithm; Staging

Mesh:

Substances:

Year:  2016        PMID: 27900518     DOI: 10.1007/s00259-016-3571-6

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  21 in total

1.  [68Ga]Gallium-labelled PSMA ligand as superior PET tracer for the diagnosis of prostate cancer: comparison with 18F-FECH.

Authors:  A Afshar-Oromieh; U Haberkorn; M Eder; M Eisenhut; C M Zechmann
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-02-04       Impact factor: 9.236

2.  (68)Ga-PSMA PET/CT imaging in primary hepatocellular carcinoma.

Authors:  Arun Sasikumar; Ajith Joy; Raviteja Nanabala; M R A Pillai; Boben Thomas; K R Vikraman
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-01-08       Impact factor: 9.236

3.  Diagnostic Efficacy of (68)Gallium-PSMA Positron Emission Tomography Compared to Conventional Imaging for Lymph Node Staging of 130 Consecutive Patients with Intermediate to High Risk Prostate Cancer.

Authors:  Tobias Maurer; Jürgen E Gschwend; Isabel Rauscher; Michael Souvatzoglou; Bernhard Haller; Gregor Weirich; Hans-Jürgen Wester; Matthias Heck; Hubert Kübler; Ambros J Beer; Markus Schwaiger; Matthias Eiber
Journal:  J Urol       Date:  2015-12-09       Impact factor: 7.450

4.  Benefit of time-of-flight in PET: experimental and clinical results.

Authors:  Joel S Karp; Suleman Surti; Margaret E Daube-Witherspoon; Gerd Muehllehner
Journal:  J Nucl Med       Date:  2008-02-20       Impact factor: 10.057

5.  (68)Ga-PSMA PET/CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate?

Authors:  Francesco Ceci; Christian Uprimny; Bernhard Nilica; Llanos Geraldo; Dorota Kendler; Alexander Kroiss; Jasmin Bektic; Wolfgang Horninger; Peter Lukas; Clemens Decristoforo; Paolo Castellucci; Stefano Fanti; Irene J Virgolini
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-05-15       Impact factor: 9.236

6.  (68)Ga-PSMA PET/CT imaging of metastatic clear cell renal cell carcinoma.

Authors:  Emre Demirci; Meltem Ocak; Levent Kabasakal; Clemens Decristoforo; Zübeyir Talat; Metin Halaç; Bedii Kanmaz
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-04-23       Impact factor: 9.236

7.  Detection of recurrent prostate cancer lesions before salvage lymphadenectomy is more accurate with (68)Ga-PSMA-HBED-CC than with (18)F-Fluoroethylcholine PET/CT.

Authors:  David Pfister; Daniel Porres; Axel Heidenreich; Isabel Heidegger; Ruth Knuechel; Florian Steib; Florian F Behrendt; Frederik A Verburg
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-03-19       Impact factor: 9.236

8.  PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions.

Authors:  A Afshar-Oromieh; A Malcher; M Eder; M Eisenhut; H G Linhart; B A Hadaschik; T Holland-Letz; F L Giesel; C Kratochwil; S Haufe; U Haberkorn; C M Zechmann
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-11-24       Impact factor: 9.236

9.  Comparison of [(18)F]DCFPyL and [ (68)Ga]Ga-PSMA-HBED-CC for PSMA-PET Imaging in Patients with Relapsed Prostate Cancer.

Authors:  Markus Dietlein; Carsten Kobe; Georg Kuhnert; Simone Stockter; Thomas Fischer; Klaus Schomäcker; Matthias Schmidt; Felix Dietlein; Boris D Zlatopolskiy; Philipp Krapf; Raphael Richarz; Stephan Neubauer; Alexander Drzezga; Bernd Neumaier
Journal:  Mol Imaging Biol       Date:  2015-08       Impact factor: 3.488

10.  PSMA PET/CT with Glu-urea-Lys-(Ahx)-[⁶⁸Ga(HBED-CC)] versus 3D CT volumetric lymph node assessment in recurrent prostate cancer.

Authors:  Frederik L Giesel; H Fiedler; M Stefanova; F Sterzing; M Rius; K Kopka; J H Moltz; A Afshar-Oromieh; P L Choyke; U Haberkorn; C Kratochwil
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-07-11       Impact factor: 9.236

View more
  4 in total

1.  Detection Threshold and Reproducibility of 68Ga-PSMA11 PET/CT in a Mouse Model of Prostate Cancer.

Authors:  Katharina Lückerath; Andreea D Stuparu; Liu Wei; Woosuk Kim; Caius G Radu; Christine E Mona; Jeremie Calais; Matthew Rettig; Robert E Reiter; Johannes Czernin; Roger Slavik; Ken Herrmann; Matthias Eiber; Wolfgang P Fendler
Journal:  J Nucl Med       Date:  2018-03-30       Impact factor: 10.057

2.  The role of additional late PSMA-ligand PET/CT in the differentiation between lymph node metastases and ganglia.

Authors:  Ian Alberts; Christos Sachpekidis; Lotte Dijkstra; George Prenosil; Eleni Gourni; Silvan Boxler; Tobias Gross; George Thalmann; Kambiz Rahbar; Axel Rominger; Ali Afshar-Oromieh
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-12-21       Impact factor: 9.236

3.  Intra-patient comparison of physiologic 68Ga-PSMA-11 and 18F-DCFPyL PET/CT uptake in ganglia in prostate cancer patients: a pictorial essay.

Authors:  Medhat M Osman; Amir Iravani; Michael S Hofman; Rodney J Hicks
Journal:  Cancer Imaging       Date:  2021-04-16       Impact factor: 3.909

4.  Celiac ganglia: can they be misinterpreted on multimodal 68Ga-PSMA-11 PET/MR?

Authors:  Ewa J Bialek; Bogdan Malkowski
Journal:  Nucl Med Commun       Date:  2019-02       Impact factor: 1.690

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.